[go: up one dir, main page]

ES8706446A1 - Un metodo para preparar una solucion acuosa estable que contiene factor de necrosis de tumores. - Google Patents

Un metodo para preparar una solucion acuosa estable que contiene factor de necrosis de tumores.

Info

Publication number
ES8706446A1
ES8706446A1 ES525228A ES525228A ES8706446A1 ES 8706446 A1 ES8706446 A1 ES 8706446A1 ES 525228 A ES525228 A ES 525228A ES 525228 A ES525228 A ES 525228A ES 8706446 A1 ES8706446 A1 ES 8706446A1
Authority
ES
Spain
Prior art keywords
aqueous solution
stable aqueous
same
necrosis factor
tumor necrosis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
ES525228A
Other languages
English (en)
Other versions
ES525228A0 (es
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Asahi Kasei Corp
Asahi Chemical Industry Co Ltd
Sumitomo Pharma Co Ltd
Original Assignee
Dainippon Pharmaceutical Co Ltd
Asahi Chemical Industry Co Ltd
Asahi Kasei Kogyo KK
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from JP57149890A external-priority patent/JPS5939829A/ja
Priority claimed from JP57172178A external-priority patent/JPS5959625A/ja
Application filed by Dainippon Pharmaceutical Co Ltd, Asahi Chemical Industry Co Ltd, Asahi Kasei Kogyo KK filed Critical Dainippon Pharmaceutical Co Ltd
Publication of ES525228A0 publication Critical patent/ES525228A0/es
Publication of ES8706446A1 publication Critical patent/ES8706446A1/es
Expired legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/525—Tumour necrosis factor [TNF]
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N1/00—Preservation of bodies of humans or animals, or parts thereof
    • A01N1/10—Preservation of living parts
    • A01N1/12—Chemical aspects of preservation
    • A01N1/122—Preservation or perfusion media
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/16—Blood plasma; Blood serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2/00—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor
    • A61L2/02—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor using physical phenomena
    • A61L2/04—Heat
    • A61L2103/05—
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Organic Chemistry (AREA)
  • Cell Biology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Inorganic Chemistry (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Environmental Sciences (AREA)
  • Dermatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Dentistry (AREA)
  • Developmental Biology & Embryology (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Hematology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

METODO PARA PREPARAR UNA SOLUCION ACUOSA ESTABLE. COMPRENDE: A) DILUIR UNA SOLUCION ACUOSA QUE CONTIENE TNF CON UNA SOLUCION ACUOSA QUE CONTIENE UN TAMPON ENTRE 5 Y 10; B) LLEVAR LA SOLUCION HASTA UNA CONCENTRACION ENTRE 102 Y 109 UNIDADES/ML DE ACTIVIDAD TNF; Y C) AÑADIR DE 1 UG A 1 MG/ML DE LA SOLUCION DE TENSIOACTIVO NO IONICO Y 10 A 500 MG/ML DE LA SUSTANCIA ACTIVA. EL TAMPON ES TRIS(HIDROXIMETIL)AMINOMETANO-HCL. LA SUSTANCIA ACTIVA SE ELIGE ENTRE D-GLUCOSA, ACIDO D-AGLUCURONICO Y TREHALOSA Y EL AGENTE TENSIOACTIVO NO IONICO SE ELIGE ENTRE UN ESTER DE ACIDO GRASO DE POLIETILENO Y UN ESTER ALQUILICO DE POLIOXIETILENO.
ES525228A 1982-08-31 1983-08-30 Un metodo para preparar una solucion acuosa estable que contiene factor de necrosis de tumores. Expired ES8706446A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP57149890A JPS5939829A (ja) 1982-08-31 1982-08-31 ガン壊死因子安定化法
JP57172178A JPS5959625A (ja) 1982-09-28 1982-09-28 ガン壊死因子を安定化する方法

Publications (2)

Publication Number Publication Date
ES525228A0 ES525228A0 (es) 1987-06-16
ES8706446A1 true ES8706446A1 (es) 1987-06-16

Family

ID=26479654

Family Applications (1)

Application Number Title Priority Date Filing Date
ES525228A Expired ES8706446A1 (es) 1982-08-31 1983-08-30 Un metodo para preparar una solucion acuosa estable que contiene factor de necrosis de tumores.

Country Status (6)

Country Link
US (1) US4457916A (es)
DE (1) DE3331003C2 (es)
ES (1) ES8706446A1 (es)
FR (1) FR2532178B1 (es)
GB (1) GB2126588B (es)
IT (1) IT1200970B (es)

Families Citing this family (112)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4920196A (en) * 1982-07-30 1990-04-24 Genentech, Inc. Human lymphotoxin
CA1213827A (en) * 1983-04-29 1986-11-12 Ricardo H. Landaburu Process for pasteurizing fibronectin
GB2187191B (en) * 1984-01-30 1989-11-01 Quadrant Bioresources Ltd Protection of proteins and the like
EP0158487B1 (en) * 1984-04-09 1991-08-28 Takeda Chemical Industries, Ltd. Stable composition of interleukin-2
JPS60258125A (ja) * 1984-06-06 1985-12-20 Hayashibara Biochem Lab Inc 蛋白性生理活性物質を含有する水溶性乾燥物
US5672347A (en) * 1984-07-05 1997-09-30 Genentech, Inc. Tumor necrosis factor antagonists and their use
US4650674A (en) * 1984-07-05 1987-03-17 Genentech, Inc. Synergistic cytotoxic composition
US6686455B1 (en) * 1984-07-05 2004-02-03 Genentech, Inc. Tumor necrosis factor
US5840522A (en) * 1984-09-20 1998-11-24 Chiron Corporation Recombinant lectins
US4677064A (en) * 1984-11-09 1987-06-30 Cetus Corporation Human tumor necrosis factor
JPS61108400A (ja) * 1984-10-31 1986-05-27 Amano Pharmaceut Co Ltd コレステロ−ルの定量法
US4743680A (en) * 1985-02-01 1988-05-10 New York University Method for purifying antihemophilic factor
EP0193917A3 (en) * 1985-03-06 1987-09-23 American Cyanamid Company Water dispersible and water soluble carbohydrate polymer compositions for parenteral administration
US5266333A (en) * 1985-03-06 1993-11-30 American Cyanamid Company Water dispersible and water soluble carbohydrate polymer compositions for parenteral administration of growth hormone
US6084073A (en) * 1985-03-25 2000-07-04 Chiron Corporation Recombinant ricin toxin
US4684623A (en) * 1985-05-02 1987-08-04 The Board Of Trustees Of The Cetus Corporation Use of tumor necrosis factor as a weight regulator
US4931385A (en) * 1985-06-24 1990-06-05 Hygeia Sciences, Incorporated Enzyme immunoassays and immunologic reagents
EP0229810B1 (en) * 1985-07-09 1991-10-16 Quadrant Bioresources Limited Protection of proteins and the like
US4868108A (en) * 1985-12-12 1989-09-19 Hygeia Sciences, Incorporated Multiple-antibody detection of antigen
US4822605A (en) * 1986-02-18 1989-04-18 Exovir, Inc. Compositions and methods employing the same for the treatment of viral and cancerous skin lesions and the like
GB8604983D0 (en) * 1986-02-28 1986-04-09 Biocompatibles Ltd Protein preservation
HU198626B (en) * 1986-05-27 1989-11-28 Sandoz Ag Process for producing pharmaceutical compositions comprising somatostatin analogues as active ingredient
US4762857A (en) * 1986-05-30 1988-08-09 E. I. Du Pont De Nemours And Company Trehalose as stabilizer and tableting excipient
US4678812A (en) * 1986-05-30 1987-07-07 E. I. Du Pont De Nemours And Company Trehalose as stabilizer and tableting excipient
US5037644A (en) * 1986-10-27 1991-08-06 Cetus Corporation Pharmaceutical compositions of recombinant interleukin-2 and formulation processes
US5183746A (en) * 1986-10-27 1993-02-02 Schering Aktiengesellschaft Formulation processes for pharmaceutical compositions of recombinant β-
CA1292686C (en) * 1986-10-27 1991-12-03 Ze'ev Shaked Pharmaceutical compositions of recombinant interleukin-2 and formulation process
EP0560411B1 (en) 1987-04-27 2000-07-26 Unilever N.V. Specific binding assays
US4808402A (en) * 1987-05-29 1989-02-28 Northwestern University Method and compositions for modulating neovascularization
CA1327161C (en) * 1987-09-01 1994-02-22 Mitsugu Kobayashi Lyophilized pharmaceutical composition of neocarzinostatin derivative
US5756450A (en) * 1987-09-15 1998-05-26 Novartis Corporation Water soluble monoesters as solubilisers for pharmacologically active compounds and pharmaceutical excipients and novel cyclosporin galenic forms
US5215743A (en) * 1988-04-13 1993-06-01 Maninder Singh Tumor necrosis factor formulations
US5078997A (en) * 1988-07-13 1992-01-07 Cetus Corporation Pharmaceutical composition for interleukin-2 containing physiologically compatible stabilizers
US5221616A (en) * 1988-07-15 1993-06-22 Quidel Corporation Prevention of spontaneous complement activation in mammalian biological fluids
US5997856A (en) * 1988-10-05 1999-12-07 Chiron Corporation Method and compositions for solubilization and stabilization of polypeptides, especially proteins
US5102788A (en) * 1988-11-21 1992-04-07 Hygeia Sciences, Inc. Immunoassay including lyophilized reactant mixture
US5223395A (en) * 1988-12-01 1993-06-29 Centocor, Inc. Immunometric assays for tumor necrosis factor-alpha and methods for preventing the loss of biological activity of tumor necrosis factor-alpha in biological samples
GB8903593D0 (en) 1989-02-16 1989-04-05 Pafra Ltd Storage of materials
USRE39497E1 (en) 1989-02-16 2007-02-27 Nektar Therapeutics Storage of materials
US6352862B1 (en) 1989-02-17 2002-03-05 Unilever Patent Holdings B.V. Analytical test device for imuno assays and methods of using same
US5384132A (en) * 1990-03-20 1995-01-24 Akzo N.V. Stabilized gonadotropin containing preparations
US5270057A (en) * 1990-03-20 1993-12-14 Akzo N.V. Stabilized gonadotropin containing preparations
TW282399B (es) * 1990-05-25 1996-08-01 Takeda Pharm Industry Co Ltd
US5653974A (en) * 1990-10-18 1997-08-05 Board Of Regents,The University Of Texas System Preparation and characterization of liposomal formulations of tumor necrosis factor
AU659645B2 (en) * 1991-06-26 1995-05-25 Inhale Therapeutic Systems Storage of materials
US5342612A (en) * 1991-12-20 1994-08-30 American Cyanamid Company Compositions for the treatment of mammalian diseases
WO1993018790A1 (en) * 1992-03-24 1993-09-30 Csatary Laszlo K Vaccine containing live virus for therapy of viral diseases and malignancies
IT1254359B (it) * 1992-05-11 1995-09-14 Serono Cesare Ist Ricerca Composizioni farmaceutiche contenenti il-6
US6582728B1 (en) 1992-07-08 2003-06-24 Inhale Therapeutic Systems, Inc. Spray drying of macromolecules to produce inhaleable dry powders
US6509006B1 (en) 1992-07-08 2003-01-21 Inhale Therapeutic Systems, Inc. Devices compositions and methods for the pulmonary delivery of aerosolized medicaments
CA2145418A1 (en) 1992-09-29 1994-04-14 John S. Patton Pulmonary delivery of active fragments of parathyroid hormone
WO1995024183A1 (en) 1994-03-07 1995-09-14 Inhale Therapeutic Systems Methods and compositions for pulmonary delivery of insulin
EP0763056B1 (en) * 1994-03-16 2000-08-09 Mallinckrodt Inc. Use of surfactants for stabilization of peptides and proteins for radiopharmaceutical use
EP0762897B1 (en) * 1994-06-02 2003-04-02 Elan Drug Delivery Limited Method of preventing aggregation of proteins/peptides upon rehydration or thawing
US6290991B1 (en) 1994-12-02 2001-09-18 Quandrant Holdings Cambridge Limited Solid dose delivery vehicle and methods of making same
JP3269824B2 (ja) * 1995-02-15 2002-04-02 ザ、プロクター、エンド、ギャンブル、カンパニー ストレス安定性泡立ち性皮膚クレンジングリキッド組成物及び個人用バス及びボディクレンジングキット
US6080707A (en) * 1995-02-15 2000-06-27 The Procter & Gamble Company Crystalline hydroxy waxes as oil in water stabilizers for skin cleansing liquid composition
CN1103585C (zh) * 1995-03-14 2003-03-26 普罗克特和甘保尔公司 分散的蒙脱石粘土作为水包油稳定剂用于洁肤液体组合物
MX9706955A (es) 1995-03-14 1997-11-29 Procter & Gamble Silice amorfo dispersado como estabilizador de aceite en agua para composicion liquida de limpieza para la piel.
US6309671B1 (en) 1995-04-14 2001-10-30 Inhale Therapeutic Systems Stable glassy state powder formulations
GB9508691D0 (en) * 1995-04-28 1995-06-14 Pafra Ltd Stable compositions
US6632648B1 (en) * 1996-05-14 2003-10-14 Elan Drug Delivery Limited Methods of terminal sterilization of fibrinogen
US5876992A (en) * 1996-07-03 1999-03-02 Molecular Biology Resources, Inc. Method and formulation for stabilization of enzymes
TW518235B (en) * 1997-01-15 2003-01-21 Akzo Nobel Nv A gonadotropin-containing pharmaceutical composition with improved stability on prolong storage
IL124275A (en) * 1997-05-02 2002-03-10 Bio Merieux Vitek Inc A method to produce sequences of nucleic acids
US6558901B1 (en) 1997-05-02 2003-05-06 Biomerieux Vitek Nucleic acid assays
US6171586B1 (en) 1997-06-13 2001-01-09 Genentech, Inc. Antibody formulation
US6991790B1 (en) 1997-06-13 2006-01-31 Genentech, Inc. Antibody formulation
US20060165606A1 (en) 1997-09-29 2006-07-27 Nektar Therapeutics Pulmonary delivery particles comprising water insoluble or crystalline active agents
US6309623B1 (en) 1997-09-29 2001-10-30 Inhale Therapeutic Systems, Inc. Stabilized preparations for use in metered dose inhalers
US6565885B1 (en) 1997-09-29 2003-05-20 Inhale Therapeutic Systems, Inc. Methods of spray drying pharmaceutical compositions
DE19758073A1 (de) * 1997-12-30 1999-07-01 Schleuning Michael Priv Doz Dr Verfahren zur Kryokonservierung menschlicher und tierischer hämatopoetischer Zellen
US6617171B2 (en) * 1998-02-27 2003-09-09 The General Hospital Corporation Methods for diagnosing and treating autoimmune disease
US6599710B1 (en) 1999-03-10 2003-07-29 The General Hospital Corporation Treatment of autoimmune disease
US20030138460A1 (en) * 2000-02-08 2003-07-24 Allergan, Inc Methods of treating animals with botulinum toxin pharmaceutical compositions
US8632785B2 (en) * 2000-02-08 2014-01-21 Allergan, Inc. Clostridial toxin pharmaceutical composition containing a gelatin fragment
US7780967B2 (en) * 2000-02-08 2010-08-24 Allergan, Inc. Reduced toxicity Clostridial toxin pharmaceutical compositions
ES2368061T3 (es) * 2000-02-08 2011-11-14 Allergan, Inc. Composiciones farmacéuticas de toxina botulínica.
US20060269575A1 (en) * 2000-02-08 2006-11-30 Allergan, Inc. Botulinum toxin pharmaceutical compositions formulated with recombinant albumin
US20030118598A1 (en) * 2000-02-08 2003-06-26 Allergan, Inc. Clostridial toxin pharmaceutical compositions
US7871598B1 (en) 2000-05-10 2011-01-18 Novartis Ag Stable metal ion-lipid powdered pharmaceutical compositions for drug delivery and methods of use
EP1280520B2 (en) 2000-05-10 2018-03-21 Novartis AG Phospholipid-based powders for drug delivery
US8404217B2 (en) 2000-05-10 2013-03-26 Novartis Ag Formulation for pulmonary administration of antifungal agents, and associated methods of manufacture and use
NZ532395A (en) 2001-10-22 2006-03-31 Dompe S Supercritical fluids processing: preparation of protein microparticles and their stabilisation
ATE508735T1 (de) 2001-12-19 2011-05-15 Novartis Ag Pulmonale verabreichung von aminoglykosiden
US7582313B2 (en) 2002-06-27 2009-09-01 The General Hospital Corporation Methods of organ regeneration using Hox 11-expressing pluripotent cells
US7628988B2 (en) 2002-06-27 2009-12-08 The General Hospital Corporation Methods and compositions for treating type 1 diabetes
WO2004045376A2 (en) * 2002-11-15 2004-06-03 The General Hospital Corporation Screening methods to identify treatments for autoimmune disease
EP1578799B8 (en) * 2002-12-02 2011-03-23 Amgen Fremont Inc. Antibodies directed to tumor necrosis factor and uses thereof
KR100560697B1 (ko) * 2003-08-06 2006-03-16 씨제이 주식회사 알부민을 함유하지 않는 에리스로포이에틴 제제
MXPA06011199A (es) 2004-03-31 2007-04-16 Genentech Inc Anticuerpos anti-tgf-beta humanizados.
GB2416122A (en) 2004-07-12 2006-01-18 Ipsen Ltd Botulinum neurotoxin composition
US20080102054A1 (en) * 2005-01-18 2008-05-01 Faustman Denise L Compositions Containing Agm Cells And Methods Of Use Thereof
GT200600112A (es) 2005-03-14 2006-11-29 Composiciiones de tigeciclina y metodos de preparacion
US8323666B2 (en) * 2005-08-01 2012-12-04 Allergan, Inc. Botulinum toxin compositions
FR2902341B1 (fr) * 2006-06-16 2011-02-25 Scras Utilisation therapeutique simultanee, separee ou etalee dans le temps d'au moins une neurotoxine botulique, et d'au moins un derive opiace
FR2910327B1 (fr) * 2006-12-22 2013-04-26 Scras Utilisation d'au moins une neurotoxine botulique pour traiter la douleur induite par les traitements therapeutiques du virus du sida.
WO2008134310A1 (en) * 2007-04-26 2008-11-06 Bayer Healthcare Llc Stabilization of liquid solutions of recombinant protein for frozen storage
FR2930447B1 (fr) * 2008-04-25 2010-07-30 Sod Conseils Rech Applic Utilisation therapeutique d'au moins une neurotoxine botulique dans le traitement de la douleur dans le cas de la neuropathie diabetique
CN102026621A (zh) * 2008-05-15 2011-04-20 巴克斯特国际公司 稳定的药物制剂
AU2010258716B2 (en) 2009-06-12 2015-11-12 Revvity Health Sciences, Inc. Compositions and methods for dehydrated storage of on-board reagents in microfluidic devices
JP5721704B2 (ja) 2009-06-12 2015-05-20 マイクロニクス， インコーポレイテッド マイクロ流体デバイス内のｔａｑポリメラーゼを乾燥保存するための再水和可能なマトリックス
EP3936137A1 (en) 2013-02-07 2022-01-12 The General Hospital Corporation Methods for expansion or depletion of t-regulatory cells
WO2015057968A2 (en) 2013-10-17 2015-04-23 The General Hospital Corporation Methods of identifying subjects responsive to treatment for an autoimmune disease and compositions for treating the same
PT3447075T (pt) 2015-05-15 2023-11-16 Massachusetts Gen Hospital Anticorpos antagonistas anti-superfamília de recetores do fator de necrose tumoral
WO2017040312A1 (en) 2015-08-28 2017-03-09 The General Hospital Corporation Agonistic anti-tumor necrosis factor receptor 2 antibodies
EP3355914B1 (en) 2015-09-29 2024-03-06 The General Hospital Corporation A composition comprising bcg for reducing cholesterol.
CN117903308A (zh) 2016-05-13 2024-04-19 综合医院公司 拮抗性抗肿瘤坏死因子受体超家族抗体
GB201612317D0 (en) 2016-07-15 2016-08-31 Philogen Spa Antibody compositions
WO2018096552A1 (en) 2016-11-28 2018-05-31 Indian Institute Of Technology, Delhi A formulation for stabilizing bio-therapeutics
CN113302205B (zh) 2018-11-15 2024-12-06 综合医院公司 激动性肿瘤坏死因子受体超家族多肽
CN112618482A (zh) * 2019-09-24 2021-04-09 江苏恒瑞医药股份有限公司 新型蛋白制剂

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3637640A (en) * 1970-05-04 1972-01-25 Diagnostic Data Inc Orgotein stabilized with saccharide process and products
DE2652636A1 (de) * 1976-11-19 1978-05-24 Hans Uwe Dr Rer Nat Wolf Verfahren zur stabilisierung von proteinen und verwandten verbindungen waehrend ihrer reinigung, isolierung und lagerung
DE3064888D1 (en) * 1979-04-30 1983-10-27 Hoechst Ag Aqueous solutions of proteins stable against denaturization, process for their manufacture, and their utilization
US4309418A (en) * 1980-03-25 1982-01-05 Sloan-Kettering Research Institute For Cancer Anti-tumor agent from human serum and process

Also Published As

Publication number Publication date
FR2532178B1 (fr) 1986-07-04
DE3331003A1 (de) 1984-03-01
GB8323271D0 (en) 1983-10-05
IT1200970B (it) 1989-01-27
US4457916A (en) 1984-07-03
DE3331003C2 (de) 1986-07-10
ES525228A0 (es) 1987-06-16
FR2532178A1 (fr) 1984-03-02
IT8367886A0 (it) 1983-08-23
GB2126588A (en) 1984-03-28
GB2126588B (en) 1986-06-25

Similar Documents

Publication Publication Date Title
ES8706446A1 (es) Un metodo para preparar una solucion acuosa estable que contiene factor de necrosis de tumores.
ES8403025A1 (es) Procedimiento para preparar una solucion de insulina estabilizada.
JPS643193A (en) Cell and tissue reparative agent
DZ1067A1 (fr) Nouvelles préparations pharmaceutiques à emission prolongée.
ES8506081A1 (es) Un metodo para liberar sustancialmente de los agentes infecciosos a una composicion que contiene una proteina terapeutica o inmunologicamente activa
HILLARP et al. Cytological demonstration of noradrenaline in the suprarenal medulla under conditions of varied secretory activity
GB1487989A (en) Pharmaceutical compositions
UA41937C2 (uk) Стабільна місцеводіюча ретиноідна композиція
ES534598A0 (es) Un procedimiento para preparar una solucion acuosa que contiene una sustancia farmaceutica soluble en lipidos
ES8307240A1 (es) Un procedimiento para la preparacion de un dihidroxi-compuesto.
NO882134L (no) Fremstilling av flunarizinholdige preparater.
FR2343806A1 (fr) Composition detergente liquide avec adjuvant actif, ayant une stabilite au stockage amelioree
ES2189038T3 (es) Sal de zinc del acido ascorbico 2-fosfato y procedimiento para su preparacion.
DK523283D0 (da) Vaskemiddel
FR2361401A1 (fr) Procede de preparation d'amoxycilline sodique
ES534215A0 (es) Una composicion para enjuagar el cabello
ES2029466T3 (es) Un metodo para la preparacion de una composicion hidrofoba que contiene enzimas y la composicion producida a partir del mismo.
IT7922968A0 (it) Medicina contenente n-d-xiloside di acido para-amminobenzoico come ingrediente attivo.
ES2000223A6 (es) Un procedimiento para preparar una composicion detergente
JPS57146722A (en) Pharmaceutical preparation having improved absorption
ES2094811T3 (es) Sintesis enzimatica de fosfatidos solubles a partir de fosfolipidos.
ES482818A1 (es) Un metodo para la produccion de una composicion farmaceuti- ca de una cefalosporina para administracion rectal.
ES2053573T3 (es) Composiciones rodenticidas que contienen derivados de 1,4-naftoquinona.
GB1307155A (en) Dimethyldichlorovinylphosphate insecticide
US4579960A (en) Stable solutions containing thimerosal

Legal Events

Date Code Title Description
PC2A Transfer of patent

Free format text: DAINIPPON PHARMACEUTICAL CO, LTD.(TITULAR AL 50%)

FD1A Patent lapsed

Effective date: 20070404